Study of TSR-033 With an Anti-PD-1



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/5/2018
Start Date:August 1, 2017
End Date:May 2021
Contact:Ying Wang, M.D., Ph.D.
Email:clinicaltrialstsr033@tesarobio.com
Phone:781-257-2449

Use our guide to learn which trials are right for you!

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating TSR-033, an
anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with
Advanced Solid Tumors in a broad range of solid tumors. Patients with disease types selected
for evaluation in this study are expected to derive clinical benefit with addition of an
anti-PD-1. The study will be conducted in two parts: dose escalation and cohort expansion.

This is a multi-center, open-label, first-in-human, Phase 1 study evaluating the anti-LAG-3
antibody of TSR-033 alone and in combination with anti-PD-1. The study will be conducted in 2
parts, with Part 1 consisting of dose escalation to determine the RP2D of TSR-033 as a single
agent (Part 1a) and in combination with an anti-PD-1 antibody (Part 1c). RP2D decisions will
be based on the occurrence of dose-limiting toxicities (DLTs), PK, as well as PDy data. These
regimens will be evaluated in patients with advanced solid tumors who have limited available
treatment options as determined by the Investigator.

Part 2 of the study will evaluate the anti-tumor activity of TSR-033 in combination with an
anti-PD-1 in patients.

Key Inclusion Criteria Part 1:

- Patients with advanced (unresectable) or metastatic solid tumor and have disease
progression after treatment with available therapies that are known to confer clinical
benefit or who are intolerant to treatment.

- Patients must have tumor tissue available.

- Female patients must have a negative serum or urine pregnancy test or be of
non-childbearing potential.

- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to
1 and adequate organ function.

Key Inclusion Criteria Part 2:

- Patients must have not been previously treated with an anti - LAG - 3, anti - PD - 1,
anti - PD - L1, or anti - PD - L2 antibody.

Key Exclusion Criteria for all:

- Known uncontrolled central nervous system metastases and - or carcinomatous
meningitis.

- History of human immunodeficiency virus (HIV), active Hepatitis B or Hepatitis C.

- Participated in another investigational study (drug or device) within 4 weeks of first
dose.

- Received prior anticancer therapy within 21 days of first dose.

- Not recovered from Adverse Events (AEs) and - or complications from major surgery
prior to first dose.

- Vaccine within 7 days of planned start of study treatment.
We found this trial at
5
sites
Tampa, Florida 33612
?
mi
from
Tampa, FL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Villejuif, Ile-de-France 94805
?
mi
from
Villejuif,
Click here to add this to my saved trials